Abstract
Agents that slow bone resorption (antiresorptive) and increase bone formation (anabolic) are used as medical treatment modalities in osteoporosis. Bisphosphonates (BP) are antiresorptive drugs that suppress osteoclastic activity and slow bone resorption and are recommended to be used as first-line therapy in osteoporosis treatment guidelines. For two decades, these drugs have been prescribed in our country and worldwide to treat osteoporosis and reduce the risk of fractures. However, according to the literature, atypical femoral fractures (AFF) are encountered in patients who have been using these drugs for more than five years. In this case report, we present the diagnosis, treatment, and recovery process of a patient who developed AFF after discontinuing long-term use of BP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Demiroglu Science University Florence Nightingale Journal of Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
